ArticlePharmacogenetics and genomics2012
Multiple genetic variants predict steady-state nevirapine clearance in HIV-infected Cambodians.
Article in Pharmacogenetics and genomics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Pooled it
- Pharmacogenetic predictors of nevirapine pharmacokinetics in Ghanaian children living with HIV with or without TB coinfection.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2021Trial
- Genetics of Nevirapine Metabolic Pathways at Steady State in HIV-Infected Cambodians.Antimicrobial agents and chemotherapy · 2017Trial
- Population pharmacokinetics of nevirapine in Malaysian HIV patients: a non-parametric approach.European journal of clinical pharmacology · 2016Trial
- Functional CYP2B6 variants and virologic response to an efavirenz-containing regimen in Port-au-Prince, Haiti.The Journal of antimicrobial chemotherapy · 2014Trial
- Clinical and genetic determinants of plasma nevirapine exposure following an intrapartum dose to prevent mother-to-child HIV transmission.The Journal of infectious diseases · 2013Trial
- Leveraging Multi-Ancestry Polygenic Risk Scores for Body Mass Index to Predict Antiretroviral Therapy-Induced Weight Gain.Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing · 2023Article
- Association ofPharmacogenomics and personalized medicine · 2021Article
- Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapy.BMC infectious diseases · 2018Article
- Review
- Severe Delayed Drug Reactions: Role of Genetics and Viral Infections.Immunology and allergy clinics of North America · 2017Review
- The Effect of Gene Variants on Levonorgestrel Pharmacokinetics When Combined With Antiretroviral Therapy Containing Efavirenz or Nevirapine.Clinical pharmacology and therapeutics · 2017Article
- Genetic Polymorphisms Affecting the Pharmacokinetics of Antiretroviral Drugs.Clinical pharmacokinetics · 2017Review
- Combined Analysis of Phase I and Phase II Data to Enhance the Power of Pharmacogenetic Tests.CPT: pharmacometrics & systems pharmacology · 2016Article
- Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa.British journal of clinical pharmacology · 2015Observational
- Perspectives on pharmacogenomics of antiretroviral medications and HIV-associated comorbidities.Current opinion in HIV and AIDS · 2015Review
- Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship.The Journal of antimicrobial chemotherapy · 2015Article
- Pharmacogenomics of antimicrobial agents.Pharmacogenomics · 2014Review
- Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi.Antimicrobial agents and chemotherapy · 2014Article
- Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants.Pharmacogenetics and genomics · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 7 institutions in 5 countries.
Funding
Abstract
objectiveIn a previous analysis involving protocol ANRS 12154, interindividual variability in steady-state nevirapine clearance among HIV-infected Cambodians was partially explained by CYP2B6 516G→T (CYP2B6*6). Here, we examine whether additional genetic variants predict nevirapine clearance in this cohort.
methodsAnalyses included Phnom Penh ESTHER (Ensemble pour une Solidarité Thérapeutique Hospitalière en Réseau) cohort participants who had consented for genetic testing. All participants were receiving nevirapine plus two nucleoside analogs. The mean individual nevirapine clearance estimates were derived from a population model developed on nevirapine concentrations at 18 and 36 months of therapy. Polymorphisms were assayed in ABCB1, CYP2A6, CYP2B6, CYP2C19, CYP3A4, CYP3A5, and NR1I2.
resultsOf 198 assayed loci, 130 were polymorphic. Among 129 individuals with evaluable genetic data, nevirapine clearance ranged from 1.06 to 5.00 l/h in 128 individuals and was 7.81 l/h in one individual. In bivariate linear regression, CYP2B6 516G→T (CYP2B6*6) was associated with lower nevirapine clearances (P=3.5×10). In a multivariate linear regression model conditioned on CYP2B6 516G→T, independent associations were identified with CYP2B6 rs7251950, CYP2B6 rs2279343, and CYP3A4 rs2687116. The CYP3A4 association disappeared after censoring the outlier clearance value. A model that included CYP2B6 516G→T (P=1.0×10), rs7251950 (P=4.8×10), and rs2279343 (P=7.1×10) explained 11% of interindividual variability in nevirapine clearance.
conclusionAmong HIV-infected Cambodians, several CYP2B6 polymorphisms were associated independently with steady-state nevirapine clearance. The prediction of nevirapine clearance was improved by considering several polymorphisms in combination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.